Navigating the Pathway from Ingenuity to Impact
Stay ahead of evolving regulatory expectations with expert analysis on cybersecurity, design controls, and QMS stability. We provide the strategic clarity needed to avoid submission gaps and accelerate your commercialization timeline.
7 guides · design controls, risk management and cybersecurity
The Business Case for Technical Training in Medical Device Development
How upstream competence reduces design rework, shortens design cycles, and accelerates product submission approval.
Read the white paperEach guide is a free download from the DQS school. You sign in, or create a free account, to get it.
Design process controls that actually work
The checkbox problem: Design controls often become an afterthought—a paperwork exercise to complete before submission rather than tools that shape the design.
Why it matters
This approach leads to predictable consequences:
- Late-stage surprises: Verification testing reveals the design doesn't meet requirements that were never properly specified.
- Validation gaps: Vague User Needs mean Design Validation cannot demonstrate the device meets them, leading to weak rationales and FDA inquiries.
- Traceability holes: Auditors find requirements without evidence or tests without linked requirements.
- 483 observations: Design control deficiencies remain among the most cited findings in FDA warning letters year after year.
Quality and Regulatory Affairs teams struggle to move engineering beyond a "paperwork" mindset to achieve true compliance.
R&D and Design Engineering teams need design controls to help catch problems early and clarify requirements rather than slowing them down.
Project Managers must plan these activities into schedules so milestones become meaningful decision points.
Design Reviews – How to maximize their value
Are your mandatory Design Reviews catching problems or just checking boxes? Our scorecard provides an objective way to assess whether your DRs are actually working.
Why it matters
Design Reviews (DR) are supposed to catch problems early—when changes are cheap. But in practice, many reviews become rubber stamps without pressure-testing the device design.
The common failure pattern we see includes:
- Pre-read materials arrive the day before (or during) the meeting.
- The design lead chairs the review of their own work.
- No one raises substantive concerns and action items are vague.
- Minutes take weeks to distribute—if they are distributed at all.
The result is that problems that should have been caught at a preliminary DR surface during Design Verification testing, or worse, in the field.
Parameter Diagrams for robust design
The robustness problem: Your device works perfectly in the lab, but failures start to appear in the field. These aren't manufacturing defects; they are robustness failures where the design didn't account for real-world variation.
Why it matters
The team likely designed for ideal conditions without systematically thinking through noise factors in actual use. Parameter Diagrams (P-Diagrams) solve this by forcing disciplined thinking about variation before design freeze.
Design Engineers need this structured method to identify failure modes and translate them into robust design requirements.
Quality Engineers want better traceability from user needs through Design Inputs to DFMEA, without gaps.
Project Managers must ensure robustness analysis happens early in development, not as an afterthought.
SAFETY Risk Analysis - How to maximize impact
The afterthought problem: Risk Analysis often gets assembled at the end to satisfy ISO 14971 on paper—rather than used to actually find and control hazards while the design can still change.
Why it matters
This approach leads to predictable consequences:
- Unexamined hazards: Hazards under fault conditions never get identified, so they surface in the field instead of in the file.
- Subjective ratings: Severity and occurrence scored by gut feel, with no defined scales or rationale—so reviewers can't follow your logic.
- Broken traceability: Risk controls with no link to design outputs or verification evidence; the chain from hazard to control to proof never closes.
- Audit findings: Incomplete and inconsistent risk files remain among the most common ISO 14971 observations year after year.
Quality and Regulatory Affairs teams own the Risk Management File and need it to survive an audit, not just exist.
R&D and Design Engineering teams need risk analysis to drive design decisions early—when controls are cheap—rather than document them after the fact.
Project Managers must build risk activities into the schedule as real gates, not a scramble before submission.
FDA Cybersecurity Requirements Decoded
If you're responsible for getting a medical device through FDA clearance—or for designing one with a robust cybersecurity posture—this guide is for you.
Why it matters
Quality and Regulatory Affairs teams need clarity on what FDA actually requires versus what's mentioned in the myriad of guidance documents. You're accountable for the success of submissions, and cybersecurity deficiencies are increasingly common reasons for rejection.
R&D and Design Engineering teams need to know what to build into the device—and when. Retrofitting cybersecurity controls after design freeze is expensive and delays timelines.
The challenge is that FDA's cybersecurity guidance spans multiple documents, references numerous standards, and uses terminology that can obscure rather than clarify. This guide cuts through that complexity.
Cybersecurity evaluations for medical devices
Cybersecurity testing is critical, but it should never be your only line of defense. Many Medical Device Manufacturers (MDM) rely solely on late-stage penetration testing. However, a single pass doesn't mean the device is secure; it just means testers didn't find a way in this time.
Why it matters
Robust security is built in layers through:
- Secure Product Development Framework (SPDF): Embedding security throughout the lifecycle.
- Threat Modeling: Systematic identification of potential failures.
- Cybersecurity Risk Management (CRM): Assessing exploitability and impact.
- Security Architecture: Design decisions that reduce attack surface.
Quality and Regulatory Affairs teams need to understand what testing evidence the FDA expects and how standards support submissions.
Software and Systems Engineering teams require clarity on test types and when to apply them during execution.
R&D Leadership must plan development timelines to include cybersecurity activities early.
FDA Cybersecurity Labeling Requirements
Why cybersecurity labeling matters: Your device may have robust controls, but if your labeling doesn't communicate them to users, FDA reviewers will find it as a gap. Under Section 524B of the FD&C Act, incomplete labeling can result in RTA decisions or delayed clearance.
Why it matters
This guide breaks down exactly what FDA expects, including:
- Specific requirements from Section VI.A of the latest FDA guidance.
- Avoiding "Refuse to Accept" (RTA) decisions due to labeling gaps.
- A verification checklist to use before your final submission.
Regulatory Affairs teams preparing 510(k), De Novo, or PMA submissions need to ensure documentation is complete before submission.
Technical Writers developing IFUs and user manuals need specific requirements to write against.
Engineering teams must know what architecture diagrams and SBOM details to provide to the labeling team.
The Capability Edge
Real-world methods from the audits, submissions, and inspections that actually happened.
The edge isn't knowing the regulation. It's implementing it.